News and media
Be part of YCare Day on November 2nd!
1 Oct 2024
Golf clubs across Québec unite on the greens...
18 Jul 2024
Clinical trial at The Neuro offers hope for...
10 Jul 2024
Health Canada Accepts for Review New Drug Submission...
Health Canada has agreed to review a New Drug Submission (NDS) for Tofersen, for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene.
A regulatory decision on the New Drug Submission is expected in early 2025. If approved, this therapy will become the first treatment in Canada to target a genetic cause of ALS.
Read the...
19 Mar 2024